Lannett (LCI) Getting Somewhat Positive News Coverage, Accern Reports

News articles about Lannett (NYSE:LCI) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Lannett earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.1431065747681 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Lannett (LCI) opened at $24.40 on Wednesday. The company has a market cap of $919.87, a price-to-earnings ratio of 21.79, a price-to-earnings-growth ratio of 1.63 and a beta of 2.85. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.90 and a current ratio of 2.52. Lannett has a 12-month low of $14.90 and a 12-month high of $30.35.

Lannett (NYSE:LCI) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.60 EPS for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.08. Lannett had a net margin of 6.67% and a return on equity of 18.23%. The company had revenue of $155.00 million during the quarter, compared to the consensus estimate of $153.62 million. During the same quarter in the prior year, the firm earned $0.77 EPS. Lannett’s quarterly revenue was down 4.1% on a year-over-year basis. sell-side analysts expect that Lannett will post 3.04 earnings per share for the current year.

A number of equities analysts have commented on LCI shares. BMO Capital Markets upped their price objective on shares of Lannett from $20.00 to $22.00 and gave the stock a “market perform” rating in a research report on Monday, November 13th. Zacks Investment Research downgraded shares of Lannett from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. ValuEngine upgraded shares of Lannett from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Finally, Oppenheimer restated a “hold” rating on shares of Lannett in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $23.60.

In other news, CEO Arthur P. Bedrosian sold 50,000 shares of the company’s stock in a transaction on Friday, November 24th. The shares were sold at an average price of $26.75, for a total transaction of $1,337,500.00. Following the transaction, the chief executive officer now directly owns 636,616 shares of the company’s stock, valued at approximately $17,029,478. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder David Farber sold 10,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $25.01, for a total transaction of $250,100.00. Following the transaction, the insider now directly owns 4,171,269 shares in the company, valued at $104,323,437.69. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 140,000 shares of company stock worth $3,681,091. Corporate insiders own 14.72% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at

About Lannett

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Insider Buying and Selling by Quarter for Lannett (NYSE:LCI)

Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with's FREE daily email newsletter.

Leave a Reply